

Assessment on the influence of TLR4 and DNA repair genes in laryngeal cancer susceptibility: a selective examination in a Romanian case control study

Corina Iulia Cornean¹, Violeta Necula¹, Marcel Cosgarea¹, Alma Aurelia Maniu^{1*}, Andreea Catana²

1. Department of Otolaryngology-Head and Neck Surgery, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj Napoca, Romania

2. Department of Molecular Sciences, University of Medicine and Pharmacy “Iuliu Hatieganu”, Romania

Abstract

Background: Tumor characterization through the study of molecular biology has become an invaluable tool in understanding cancer development and evolution due to its relationship with chromosomal mutations, alterations or aberrations. The purpose of this study was to investigate the involvement of genes such as TLR-4 and DNA repair pathways (XRCC1 and XPD) in laryngeal cancer susceptibility in a Romanian population. **Method:** We performed a case-control study on 157 laryngeal cancer patients and 101 healthy controls. Genetic testing was carried out using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism. **Results:** We identified the Gln allele of the XPD Lys751Gln polymorphism as an individual risk factor in laryngeal cancer development (Gln vs Lys, adjusted OR=1.65, 95%CI=1.13-2.40, P=0.008). Subjects with the mutant homozygote variant (Gln/Gln) had a two fold increase in cancer risk (adjusted OR=2.18, 95%CI=1.06-4.47, p=0.028) when compared to the reference wild type genotype (Lys/Lys). Stratification by sex and age, identified males under 62 years as the most susceptible group with an almost three fold risk (adjusted OR=2.94, 95%CI=1.31-6.59, p=0.007) for the dominant model (Lys/Gln+Gln/Gln). No associations were found for TLR-4 Thr399Ile, XRCC1 Arg194Trp and XRCC1 Arg399Gln. **Conclusion:** The results of the study show that the XPD Lys751Gln polymorphism may be among other independent risk factors for developing laryngeal cancer where as TLR-4 Thr399Ile, XRCC1 Arg194Trp and XRCC1 Arg399Gln show no such association. However, we consider the relative small number of the subjects selected for this analyses a possible limitation towards the real influence the obtain results may pertain in laryngeal cancer evolution.

Keywords: single nucleotide polymorphism, laryngeal cancer; Genetic susceptibility, TLR-4 Thr399Ile, XRCC1 Arg194Trp

Received: 10th August 2020; Accepted: 11th December 2020; Published: 2nd January 2021

* **Corresponding author:** Alma Maniu, Department of Otolaryngology-Head and Neck Surgery, University of Medicine and Pharmacy “Iuliu Hatieganu”, 4-6 Clinicilor, Cluj-Napoca 400006, Romania. E-mail: almacjro@yahoo.com

Introduction

Laryngeal cancer represents one of the most influential candidates for malignancy within Head and Neck cancers (HNC) with a favorable and stable 5-year survival rate (61% -67%) over the past decades (1), yet severe and lasting impact on the patients' quality of life. As one of the most susceptible regions of the human body towards chronic inflammation, the larynx is considered a prime contender towards malignancy. The risks of such exposure have been well documented over the years by identifying the triggers and hallmarks of cancer-related inflammation (2, 3), a process which tends to create a specific microenvironment whose unique composition may then foster the neoplastic process (4). Although the most common form of presentation to date is that of a squamous cell carcinoma (SCC), the particular anatomical conformation of the larynx offers the possibility of numerous tumor sites, each one with characteristic symptoms, specific treatment and prognostic (5, 6).

Toll-like receptors (TLRs) are a class of proteins belonging to the family of pattern recognition receptors (PRR) which play a significant role in innate immunity. They activate cellular signalling pathways after initial detection of the pathogenic microorganism by PRRs and induce immune response genes (7, 8). Without the signals provided by toll-like receptors, the regulation of both the innate and adaptive immune responses may be deficient. As such, developed neoplastic cells have the capability to by-pass the body's immune response by turning the immune balance in their favour (9). Ten isoforms (TLR 1-10) are found in humans, of which TLR-4 is expressed in both normal cells and in cancer cells (10). TLR-4 has been widely studied and linked as an independent carcinogenetic risk factor with overall high associations for a large variety of cancer forms (11, 12). DNA repair genes hold a key role in maintaining genome integrity by operating on specific types

of damaged DNA. The three major DNA repair pathways implicated in this process are nucleotide excision repair (NER), base excision repair (BER) and double strand break (DSB) (13, 14). The implication of DNA repair genes in the carcinogenetic process has become a widely studied subject towards understanding malignancy (15). As part of BER pathway, the x-ray repair cross-complementing group 1 (XRCC1) gene acts along with specific ligase and polymerases in order to provide DNA repair (16). Amongst the many single nucleotide polymorphisms (SNPs) of the XRCC1 gene, codons 194 (Arg>TRP), 280 (Arg> His) and 399 (Arg> Gln) are the most common and the most studied coding region polymorphisms in regard to cancer susceptibility with overall significantly increased risk towards a wide range of neoplasms including head and neck cancers (17-20).

The Xeroderma pigmentosum Type D (XPD) protein is encoded by the ERCC2 (excision repair cross-complementation group 2) gene, a subunit of the TFIIH (Transcription factor II Human) complex implicated in the transcription of various protein-coding genes and NER-pathways (21). It holds a critical role for the cell viability by unwinding the double helix DNA in the 5'-3' direction after damage is initially recognized, thus allowing for other proteins to then remove the damaged section and replace it with the correct DNA strand (22). The Lys751Gln polymorphism is located within the carboxy-terminal domain (CTD) of XPD protein (23). Mutations in the XPD C-terminus cause binding issues of the p44 subunit of TFIIH which reduces DNA repair activity and increases cancer susceptibility (24). Several publications report on the existing link between *XPD*_{Lys751Gln} polymorphism and cancers such as breast (25), prostate (26), lung (27) or the gastrointestinal tract (28).

Case-control studies have been widely used over the last few years in order to assess the relationship between genetics and malignancy genetic associations. However, there are still few stud-

ies to date regarding a Romanian population base. The purpose of this study was to establish whether the *TLR-4*_{Thr399Ile}, *XPB*_{Lys751Gln}, *XRCC1*_{Arg194Trp} and *XRCC1*_{Arg399Gln} polymorphisms are involved in laryngeal cancer susceptibility in this ethnic group.

Material and Methods

Patients and controls

A total of 258 individuals were enrolled in this case-control study. The study group included 157 laryngeal cancer patients and 101 healthy volunteers with no history of laryngeal pathology from the Departments of Otorhinolaryngology and Genetics, Cluj County Emergency Clinical Hospital, Romania. The research protocol was approved by the Ethics Committee of 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca and it complies with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects and/or animals (29). Informed consent was obtained from all participants regarding genetic testing.

Genotyping analysis of studied polymorphisms

*TLR-4*_{Thr399Ile}

Extraction of the genomic DNA from the *TLR-4* gene Thr399Ile polymorphism (rs4986791) was performed on EDTA (ethylenediaminetetraacetic acid) treated venous peripheral blood samples (400 µL) with the help of the Wizard Genomic DNA Purification Kit, Promega (Madison, Wisconsin, USA). Samples were initially stored in a frozen state (-20°C) before molecular processing. Genotyping was performed using Polymerase Chain Reaction followed by enzymatic Restriction Fragment Length Polymorphism (PCR-RFLP) according to manufacturer's instructions. Subsequent PCR methodology towards fragment amplification of the obtained 100 ng of genomic DNA required the following prim-

ers (F5'-CTACCAAGCCTTGAGTTTCTG-3' and R3'-AAGCTCAGATCTAAATACT-5') and specific cycling conditions: 94°C for 5 minutes; 35 cycles at 94°C for 40 seconds, 58°C for 45 seconds, 72°C for 40 seconds; followed by an additional 72°C for 10 minutes at the end. The final amplified products were digested by 5 units of restriction enzyme (BslI) at 37°C and then separated using gel electrophoresis (3% agarose gel). Genotype variants were detected by ethidium bromide staining which identified 3 distinct banding patterns corresponding to the 3 genotypes: wild type (AA), heterozygote (AG) and variant homozygote (GG).

*XPB*_{Lys751Gln}

The genotyping of ERCC2/XPB Lys751Gln (rs13181) polymorphism was performed using the multiplex PCR-RFLP technique on DNA initially extracted from EDTA-treated peripheral blood samples (300 µL) using Wizard Genomic DNA Purification Kit (Promega, Madison, USA). The obtained 100 ng of genomic DNA were amplified in a total of 25 µL reaction mixture before PCR was carried out using a thermal cycler (Eppendorf Mastercycler Thermal Cycler) with the following steps: 1 minute denaturation at 96 °C; 30 cycles of denaturation at 94 °C for 30 seconds each, followed by primer annealing at 60 °C for 30 seconds and primer extension at 72 °C for 1 minute. The final step consisted of a 2 minutes extension at 72 °C. After PCR amplification, the obtained products were digested with 4 units of Tfi enzyme (Fermentas) for 6 hours. Subsequent detection of the resulting variants (wild type Lys/Lys, heterozygote Lys/Arg and mutant homozygote Arg/Arg) was carried out using gel electrophoresis (2% agarose gel transilluminated with ultraviolet light).

*XRCC1*_{Arg194Trp, Arg399Gln}

Genomic DNA extraction of XRCC1 gene Arg194Trp (rs1799782) and Arg399Gln (rs25487)

polymorphisms was carried out on samples of 300 μ L EDTA-treated venous blood with the help of two purification kits: Wizard® genomic DNA purification kit (Promega Corporation, Fitchburg, WI, USA) and ZymoBead™ genomic DNA kit (Zymo Research Corporation, Irvine, CA, USA). Both polymorphisms of the XRCC1 gene (Arg194Trp and Arg399Gln) were genotyped using the multiplex PCR–RFLP technique. The obtained DNA, a total of 100 ng, was then amplified in a total volume of 25 μ L of specific reaction mixture and put through successive thermocycling conditions (Mastercycler® Gradient; Eppendorf AG, Hamburg, Germany): 94°C for 5 minutes, 30 cycles of 94°C for 30 seconds, 62°C for 1 minute, 72°C for 45 seconds, 72°C for 5 minutes. Resulting genotypes were identified using the following criteria: for codon 194 the common allele corresponded with Arg (293 bp fragment) and the variant allele with Trp (313 bp fragment); for codon 399 the common allele corresponded with Gln (375 bp fragment) and the variant allele with Arg (240 bp fragment).

Statistical analysis

Statistical analysis was carried out using Epiinfo 7 software for the Windows operating system. Two sided chi-square test (χ^2) and Fisher's exact test were used in order to compare the two groups of categorical data. The obtained data was then subjected to comparative analysis against the reference wild type variants for specific genetic models (heterozygote, homozygote, dominant, recessive and allele-contrast). Multivariate logistical regression with adjustment for gender and age (in years) was performed in order to measure the association between exposure and outcome parameters. The genotypes of TLR-4_{Thr399Ile}, XPD_{Lys751Gln}, XRCC1_{Arg194Trp} and XRCC1_{Arg399Gln} were recorded as dummy variables for logistic regression. Results were considered statistically significant for a p-value of <0.05.

Results

Distribution of demographic characteristics in study groups

Of the total 157 laryngeal cancer subjects included, 145 were males (92.36%) and 12 females (7.64%) as shown in Table I. Although male subjects were more common in cases than in controls than females, there were no statistically significant differences between genders (P=0.1321). Age varied in patients from 21-83 with an average diagnosis age of 62 years (standard deviation 9.14 years) for cases and 61 years (standard deviation 6.59 years) for controls. The most common age group was 55-65 years with a total of 74 (47.13%) cases and 44 (43.56%) controls, the results being statistically significant (P=0.021).

Distribution of genotype frequencies in patients and controls

We analysed TLR-4_{Thr399Ile}, XPD_{Lys751Gln}, XRCC1_{Arg194Trp} and XRCC1_{Arg399Gln} polymorphisms in 157 laryngeal cancer patients and 101 healthy controls. The distribution of genotypes and allele frequencies are presented in Table II.

Table I. Demographic characteristics of the studied groups.

Variables	Cases (%)	Controls (%)	P-value ^a
Gender			
Male	145 (92.36)	92 (91.09)	0.1321
Female	12 (7.64)	9 (8.91)	
Age Mean	60.541	62	
Age Range	21-83		
<45	8 (5.10)	0 (0)	0.0026
46-55	32 (20.38)	23 (22.77)	
56-65	74 (47.13)	44 (43.56)	
66-75	35 (22.29)	33 (32.67)	
>75	8 (5.10)	1 (0.99)	

a: Abbreviation: Two-sided chi square test (χ^2) test.

b: Statistically significant result, p<0.05 in bold.

Chi-square test was used on the control group in order to calculate Hardy–Weinberg equilibrium (HWE) according to the theory: $p^2 + 2pq + q^2$, where p is the frequency of the “A” allele and q is the frequency of the “a” allele in the population. Deviation from HWE was calculated using internet based programs (<https://wpcalc.com/en/equilibrium-hardy-weinberg/>; <http://www.dr-petrek.eu/links.html> (HWE.xls)). Only the observed genotype frequencies of TLR-4^{Thr399Ile} in the control group showed no significant departure from HWE (P=0.21, data not shown) while

*XPD*_{Lys751Gln}, *XRCC1*_{Arg194Trp} and *XRCC1*_{Arg399Gln} were all significantly deviated (P=0.015, P=0.000067, P=0.0011 respectively). The lack of balance may be caused due to the type of subjects we were able to obtain at the moment of this study for the purpose of performing this type of genetic analyses, the relative small number of subjects included in the study and the possible selection bias in hospital-based case-control studies, genetic drift in the control group.

The observed genotype distribution in patients and controls was not statistically significant

Table II. Distribution of *XRCC1*Arg194Trp, *XRCC1*Arg399Gln, *XPD*Lys751Gln and *TLR-4*Thr399Ile polymorphisms in cases and controls.

Polymorphism	Cases N=157 (%)	Controls N=101 (%)	χ^2	P-value
<i>XRCC1</i> _{Arg194Trp}				
AA	92 (58.60)	64 (63.37)	0.843	0.655
AT	37 (23.57)	23 (22.77)		
TT	28 (17.83)	14 (13.86)		
A Allele	221 (70.38)	151 (74.75)	1.166	0.28
T Allele	93 (29.62)	51 (25.25)		
<i>XRCC1</i> _{Arg399Gln}				
Arg/Arg	97 (61.78)	66 (55.35)	0.783	0.675
Arg/Gln	37 (23.57)	24 (23.76)		
Gln/Gln	23 (14.65)	11 (10.86)		
Arg Allele	231 973.57)	156 (77.23)	0.878	0.348
Gln Allele	83 (26.43)	46 (22.77)		
<i>XPD</i> _{Lys751Gln}				
Lys/Lys	35 (22.29)	14 (13.86)	5.665	0.588
Lys/Gln	59 (37.58)	32 (31.68)		
Gln/Gln	63 (40.13)	55 (54.46)		
Lys Allele	185 (58.92)	142 (70.30)	6.857	0.008^b
Gln Allele	129 (41.80)	60 (29.70)		
<i>TLR-4</i> _{Thr399Ile}				
AA	104 (66.24)	71 (70.30)	0.868	0.647
AG	43 (27.39)	26 (25.74)		
GG	10 (6.37)	4 (39.15)		
A Allele	251 (79.94)	168 (83.17)	0.841	0.359
G Allele	63 (20.06)	34 (16.83)		

a: Abbreviation: Two-sided chi square test (χ^2) test; A-Adenine; G-Guanine; T-Thymine; Arg-Arginine; Trp-Tryptophan; Gln-Glutamine; Ile-Isoleucine; Lys-Lysine; b: Statistically significant results compared with control group, $p < 0.05$, in bold; c: Genotypes: homozygote wild-type (AA, Arg/Arg, Lys/Lys, AA), heterozygote (AT, Arg/Gln, Lys/Gln, AG), mutant homozygote (TT, Gln/Gln, Gln/Gln, GG).

for the TLR-4^{Thr399Ile}, *XRCC1*^{Arg194Trp} and *XRCC1*^{Arg399Gln} polymorphisms, as shown in Table II. For *XPB*^{Lys751Gln}, the distribution of frequency in the Lys/Lys, Lys/Gln and Gln/Gln genotypes was (22.29%, 37.58%, 40.13 respectively) in case and (13.86%, 31.68%, 54.46 respectively) in controls. Although the Gln/Gln genotype was the more common variant in cases than in controls, the difference in distribution was not statistically significant ($P=0.588$). Distribution by allele frequency found the Gln allele to be more common in cases than in controls, the difference being statistically significant ($P=0.008$)

Comparative analysis of genetic models

In order to evaluate the risk for laryngeal cancer in the study group compared with the control group, comparative analysis was performed for TLR-4^{Thr399Ile}, *XPB*^{Lys751Gln}, *XRCC1*^{Arg194Trp} and *XRCC1*^{Arg399Gln} polymorphisms based on five genetic models (heterozygote, mutant homozygote, dominant, recessive and allele contrast). Crude and adjusted OR with 95% CI was calculated using multivariate logistic regression as shown in Table III. We investigate the role innate factors such as gender and age have as modulating factors for laryngeal cancer development when assessed in the presence of the different genetic variants belonging to the studied polymorphism. Other confounding factors such as external risk factors were excluded from the investigation process.

Results for TLR-4^{Thr399Ile}, *XRCC1*^{Arg399Gln} and *XRCC1*^{Arg194Trp} genotypes showed no evidence for increased cancer risks association in any of the studied genetic models.

Adjusted values for *XPB*^{Lys751Gln} show the Gln allele as an individual risk factor for laryngeal cancer development (Gln vs Lys, adjusted OR=1.65, 95%CI=1.13-2.40, $P=0.008$), while individuals carrying the Gln allele express a two fold risk (adjusted OR=2.18, 95%CI=1.06-4.47, $P=0.028$) in the mutant homozygote genotype (Gln/Gln)

when compared to the reference wild type genotype (Lys/Lys). We also observed positive associations between *XPB*^{Lys751Gln} and laryngeal cancer after secondary stratification based on gender and age (in years) in a logistic regression model as shown in Table IV. After controlling for sex, younger subjects (age<62 years) show a two fold risk (OR=2.37, 95%CI=1.12-4.99, $P=0.021$) for Gln allele carriers in the dominant model (Lys/Gln+Gln/Gln). Stratification by gender could not find positive associations in either males or females. However, subsequent stratification in a double model (gender and age) highlighted the Gln/Gln genotype as the predominant risk variant in male laryngeal cancer patients under 62 years of age with an almost four fold risk (adjusted OR=3.70, 95%CI=1.10-12.35, $P=0.02$) followed by the dominant model with an almost three fold risk (adjusted OR=2.94, 95%CI=1.31-6.59, $P=0.007$) and the heterozygote variant (Lys/Gln) with a two fold risk (OR=2.61, 95%CI=1.04-6.51, $P=0.033$). No such associations were identified for TLR-4^{Thr399Ile}, *XRCC1*^{Arg399Gln} and *XRCC1*^{Arg194Trp} polymorphisms after stratification by gender and age (data not shown).

Discussion

Laryngeal cancer is one of the predominant forms of Head and Neck cancers. The contribution of multiple environmental and genetic factors plays an important role in the overall characterization of this particular malignancy (30). To date, it is one of the most studied cancers in regard to genetic susceptibility. To our knowledge, this is the first study to perform a comparative analysis of the TLR-4^{Thr399Ile}, *XPB*^{Lys751Gln}, *XRCC1*^{Arg194Trp} and *XRCC1*^{Arg399Gln} polymorphisms on patients diagnosed with laryngeal cancer in a Romanian population.

The results of our study showed that there was no association between the TLR-4^{Thr399Ile} polymorphism and laryngeal cancer risk in any ge-

netic model. Studies in TLR polymorphisms and laryngeal cancer are still limited to this day in terms of genotyping specific polymorphisms

towards identifying cancer risk. Literature data previously outlined the expression of TLR-4 in the laryngeal carcinoma microenvironment in

Table III. Comparative analysis models of XRCC1Arg194Trp, XRCC1Arg399Gln, XPD Lys751Gln and TLR-4Thr399Ile in laryngeal cancer patients.

Genotypes	Cases N=157 (%)	Controls N=101 (%)	Crude OR (95% CI)	P-value	Adjusted OR ^c (95% CI)	P-value
XRCC1Arg194Trp						
Wild type variant (AA)	92 (71.32%)	64 (73.56%)	(ref) 1.00 ^b		(ref) 1.00 ^b	
Heterozygote (AT)	37 (28.68%)	23 (26.44%)	1.12 (0.58-2.17)	0.758	1.11 (0.60-2.05)	0.717
Homozygote mutant (TT)	28 (23.33%)	14 (17.95%)	1.39 (0.64-3.09)	0.477	1.39 (0.67-2.84)	0.361
Dominant (AT+TT) vs AA	65 (41.40)	37 (36.63)	1.22 (0.70-2.11)	0.514	1.22 (0.73-2.04)	0.443
Recessive TT vs (AA+AT)	129 (82.17)	87 (13.86)	1.35 (0.64-2.93)	0.492	1.34 (0.67-2.70)	0.394
Allele contrast model (Trp vs Arg)						
Allele Arg	93 (29.62%)	51 (25.25%)	(ref) 1.00 ^b	0.314	1.245 (0.835-1.857)	0.278
Allele Trp	221 (70.38%)	151 (74.75%)	1.25 (0.82-1.90)			
XRCC Arg399Gln						
Wild type variant (Arg/Arg)	97 (61.78%)	66 (65.35%)	(ref) 1.00 ^b		(ref) 1.00 ^b	
Heterozygote (Arg/Gln)	37 (27.61%)	24 (26.67%)	1.05 (0.58-2.17)	1	1.04 (0.57-1.91)	0.876
Homozygote mutant (Gln/Gln)	23 (19.17%)	11 (14.29%)	1.42 (0.64-3.09)	0.442	1.42 (0.64-3.11)	0.371
Dominant (Arg/Gln+Gln/Gln) vs Arg/Arg	60 (38.22)	35 (34.65)	1.17 (0.70-2.11)	0.598	1.16 (0.69-1.96)	0.561
Recessive Gln/Gln vs (Arg/Arg+Arg/Gln)	134 (85.35)	90 (89.11)	1.4 (0.62-3.32)	0.453	1.40 (0.65-3.02)	0.378
Allele contrast model (Gln vs Arg)						
Allele Arg	83 (26.43%)	46 (22.77%)	(ref) 1.00 ^b	0.404	1.21 (0.80-1.82)	0.346
Allele Gln	231 973.57%)	156 (77.23%)	1.22 (0.79-1.88)			
XPD Lys751Glu						
Wild type variant (Lys/Lys)	63 (51.64%)	55 (63.22%)	(ref) 1.00 ^b		(ref) 1.00 ^b	
Heterozygote (Lys/Gln)	59 (48.36 %)	32 (36.78%)	1.61 (0.88-2.94)	0.1195	1.60 (0.91-2.82)	0.095
Homozygote mutant (Gln/Gln)	35 (35.71%)	14 (20.29%)	2.18 (1.01-4.84)	0.0383	2.18 (1.06-4.47)	0.028^d
Dominant (Lys/Gln+Gln/Gln) vs Lys/Lys	94 (59.87)	46 (45.54)	1.78 (1.04-3.05)	0.0294	1.78 (1.07-2.95)	0.024
Recessive Gln/Gln vs (Lys/Lys+Lys/Gln)	122 (77.71)	87 (86.14)	1.78 (0.87-3.80)	0.1051	1.78 (0.90-3.51)	0.086
Allele contrast model (Gln vs Lys)						
Allele Lys	129 (41.80%)	60 (29.70%)	(ref) 1.00 ^b	0.0084	1.65 (1.13-2.40)	0.008^d
Allele Gln	185 (58.92%)	142 (70.30%)	1.65 (1.11-2.45)			
TLRThr399Ile						
Wild type variant (AA)	104 (69.33%)	71 (24.47)	(ref) 1.00 ^b		(ref) 1.00 ^b	
Heterozygote (AG)	46 (30.67%)	23 (24.47%)	1.13 (0.73-2.57)	0.771	1.12 (0.63-2)	0.677
Homozygote mutant (GG)	10 (8.77%)	4 (5.33%)	1.71 (0.46-7.73)	0.571	0.58 (0.17(1.94)	0.367
Dominant (AG+GG) vs AA	53 (33.76)	30 (29.70)	1.20 (0.68-2.15)	0.585	1.20 (0.70-2.06)	0.495
Recessive GG vs (AA+AG)	147 (93.63)	97 (96.04)	1.64 (0.45-7.39)	0.575	1.64 (0.503-5.409)	0.395
Allele contrast model (G vs A)						
Allele A	63 (20.06%)	34 (16.83%)	(ref) 1.00 ^b	0.419	1.24 (0.78-1.96)	0.356
Allele G	251 (79.94%)	168 (83.17%)	1.24 (0.76-2.03)			

a: Abbreviation: OR-odds ratio; 95% CI-95% confidence interval; FDR-false discovery rate; b: Reference categories (OR=1): the wild type genotype and allele for each individual polymorphism; c: Adjusted OR, calculated in a logistic regression model without control for gender and age; d: Bold values as statistically significant after application of FDR correction, $p < 0.05$.

Table IV. Stratification analysis of the association between the XPD_{Lys751Gln} polymorphism and laryngeal cancer

Variables	Number of cases			Number of controls			Adjusted OR ^c (95% CI)			
	Lys/ Lys	Lys/ Gln	Gln/ Gln	Lys/ Lys	Lys/ Gln	Gln/ Gln	Heterozygote	Homozygote mutant	Dominant	Recessive
Age (in years)										
<62	34	30	19	28	13	4	1.90 (0.83-4.31), p=0.120	3.91 (1.19-12.83), p=0.014	2.37 (1.12-4.99), p=0.021^d	3.04 (0.96-9.58), p=0.039
≥62	29	29	16	27	19	10	1.42 (0.65-3.10), p=0.376	1.48 (0.57-3.84), p=0.407	1.44 (0.71-2.91), p=0.303	1.26 (0.52-3.05), p=0.593
Gender										
Male	58	55	32	52	27	13	1.82 (1.00-3.30), p=0.0447	2.20 (1.04-4.64), p=0.0328	1.94 (1.14-3.31), p=0.0129	1.72 (0.84-3.48), p=0.1230
Female	5	4	3	3	5	1	0.48 (0.06-3.35), p=0.455	0.20 (0.01-2.91), p=0.212	0.7 (0.11-4.23), p=0.696	0.29 (0.02-3.45), p=0.303
Age-Gender										
Males <62	31	27	17	27	9	4	2.61 (1.04-6.51), p=0.033^d	3.70 (1.10-12.35), p=0.021^d	2.94 (1.31-6.59), p=0.007^d	2.63 (0.82-8.46), p=0.081
Males ≥62	27	28	15	25	18	9	1.44 (0.64-3.21), p=0.372	1.54 (0.57-4.15), p=0.386	1.47 (0.71-3.04), p=0.294	1.30 (0.52-3.26), p=0.569
Females <62	4	3	2	1	4	0	0.18 (0.01-2.66), p=0.187	- ^c	0.31 (0.02-4.03), p=0.348	- ^c
Females ≥62	1	1	1	2	1	1	2 (0.05-78.24), p=0.709	1 (0.01-50.39), p=1	2 (0.09-44.34), p=0.657	1.5 (0.05-40.74), p=0.809

a: Abbreviation: OR-odds ratio; 95% CI-95% confidence interval; b: Adjusted OR for covariates such as gender and age (in years) in a logistic regression model for each stratum; c: OR could not be calculated due to zero values in one category; d: Bold values as statistically significant after application of FDR correction, $p < 0.05$.

works by Szczepański et al. (31) and Sikora et al. (32), who report on how laryngeal carcinoma cells mainly express three of the ten human isoforms: TLR2, TLR3 and TLR4. Bergman et al. found the heterozygous genotype of TLR-4_{Thr399Ile} in head and neck cancer squamous cell carcinoma (HNSCC) patients to have reduced disease-free survival rates (33). In a meta-analysis by Ding et al. TLR 4 polymorphisms were associated with decreased cancer risk in both Asian and Caucasians, but not TLR-4_{Thr399Ile} who showed no such association (34).

Research on DNA repair genes has previously reported on the implication of the XRCC1 gene in laryngeal cancer development with various results throughout the years. Alimu et al. (35) identified that carriers of the heterozygote and mutant homozygote variants of both *XRCC1*

Arg194Trp and *XRCC1*_{Arg399Gln} may be associated with laryngeal cancer in an Asian population group. In a meta-analysis, Li et al. (36) could only link the *XRCC1*_{Arg399Gln} polymorphism under the homozygote model with increased cancer risk for laryngeal cancer (OR = 1.29, 95% CI= 1.00–1.65, $P = 0.05$). Olshan et al. (37) reported a weak elevation in the risk for head and neck cancer (HNC) patients for the *XRCC1*_{Arg194Trp} polymorphism (OR=1.3, 95% CI 0.6-2.9) and a decreased risk for the *XRCC1*_{Arg399Gln} polymorphism (OR=0.6; 95%CI= 0.4-1.1). The same decreased cancer risk was noted for HNC in studies by Huang et al. (38) for the homozygote model of *XRCC1*_{Arg399Gln} (OR=0.56, 95% CI= 0.32-0.94) and by Hu et al. (39) for Trp allele carriers of the *XRCC1*_{Arg194Trp} polymorphism (OR=0.89, 95% CI= 0.81-0.98).

The results of our study showed no association between the *XRCC1*_{Arg194Trp} and *XRCC1*_{Arg399Gln} polymorphisms and the risk of laryngeal cancer in our Romanian population. According to the literature, the same lack of association between *XRCC1* gene polymorphisms and laryngeal cancer was reported in works by Varzim et al. (40), Chen et al. (41) and Wu WQ et al. (42). In reference to HNC susceptibility, several articles also affirm no such relationship for the *XRCC1* polymorphisms (43-45).

Our analysis in the *XPB*_{Lys751Gln} polymorphism identified a high risk association towards laryngeal cancer development in Gln allele carriers. Young subjects possessing the Gln/Gln genotype reported a two fold cancer risk. We observed a directly proportionate amplification in risk once the subjects were also distributed according to sex. The greatest magnitude towards cancer risk in the studied population was thus found in male patients, age under 62 years, in the mutant homozygote variant, the dominant model and finally the heterozygote model. This modification in risk according to individual factors such as age and gender is in accordance with the literature data as both the male-to-female incidence ratio and the age distribution in laryngeal cancer shows predominance towards male patients between 40-60 years in age (6). The obtained results regarding the genetic models of the *XPB*_{Lys751Gln} polymorphism are in agreement with other literature data reported on this subject. Lin et al. (46) observed high risk association for both laryngeal and nasopharyngeal cancers in the same heterozygote and dominant models while Mitral et al. (25) observed an increase in risk for the mutant homozygote (OR=1.680, 95% CI=1.014-2.784), heterozygote (OR=1.531, 95% CI=1.092-2.149) and dominant (OR 1.560, 95% CI=1.128-2.158) genetic model in HNSCC. Yuan et al. (47) found the same dominant model linked with HNC (OR= 1.12, 95%CI= 1.03-1.22, P= 0.01), while the heterozygote model was

borderline significant (OR=1.08, 95%CI= 0.99-1.19, P= 0.08). As literature has also confirmed that the two *XPB* variant alleles may be related to decreased NER function and thus lower levels of DNA damage repair attributes as opposed to the more common wild-type alleles (48), it also highlights how the more predominant influences of the *XPB*_{Lys751Gln} polymorphism in carcinogenesis seem to belong to Gln allele carriers in terms of development and poorer survival rates (49). Indeed, this characteristic cannot yet be considered a wholly independent factor, but it may be an additive one especially when further analyzed with other possible independent factors, innate or environmental. After all, a lack of associations between the *XPB*_{Lys751Gln} polymorphism and cancer has also been observed in the literature and thus further analysis is required in order to correctly assess this apparent particularity of the *XPB* variants (50, 51).

In terms of the limits of our study, the relative small number of subjects subjected to genetic testing as well as their overall characteristics at the moment this study took place must be considered along with the population type. We only included Caucasians of Romanian ancestry, as such the genetic characteristic of this ethnic group may present particular variations in terms of characteristics typical of Eastern Europe populations. Future studies with large-scales populations and multiple ethnic groups are still needed in order to determine the precise genetic distribution of alleles and variants of these important genes in terms of further evaluating the role genetic mutations within them have towards laryngeal cancer susceptibility.

Conclusion

Results highlight no evidence of a relationship between the *TLR-4*_{Thr399Ile}, *XRCC1*_{Arg194Trp} and *XRCC1*_{Arg399Gln} polymorphisms and laryngeal cancer. Gln carriers of the *XPB*_{Lys751Gln} polymorphism

showed individual association with laryngeal cancer risk in the mutant homozygote variant as well as increased risk when patients were then stratified by gender and age. The overall results of our study support the hypothesis that the $XPD_{Lys751Gln}$ polymorphism may contribute to the risk of developing laryngeal cancer in this ethnic group. However, it is possible that our results may be caused by chance with the stratified analysis model due to the number of subjects included in the study as well as the possible selection bias of hospital based subjects. Thus, we consider our results as preliminary and in need of further validation from larger studies.

Abbreviations

TLR: toll-like receptors
 DNA: deoxyribonucleic acid
 HNC: head and neck cancers
 SCC: squamous cell carcinoma
 PRR: pattern recognition receptors
 NER: nucleotide excision repair
 BER: and base excision repair
 DSB: double strand break
 XRCC1: x-ray repair cross-complementing group 1
 SNP: single nucleotide polymorphism
 Arg: arginine
 Trp: tryptophan
 Gln: glutamine
 Ile: Isoleucine
 Lys: lysine
 A: adenine
 G: guanine
 T: thymine
 XPD: xeroderma pigmentosum type D
 ERCC2: excision repair cross-complementation group 2
 TFIIH: transcription factor II human complex
 CTD: carboxy-terminal domain
 ETDA: ethylenediaminetetraacetic acid
 PCR-RFLP: polymerase chain reaction-restriction

fragment length polymorphism

OR: odds ratio

CI: confidence interval

HNSCC: head and neck squamous cell carcinoma

FDR: false discovery rate

Acknowledgements

This work is part of "Iuliu Hațieganu" University of Medicine and Pharmacy doctoral programme.

Authors' contributions

CIC (Conceptualization, Acquisition of data, Analysis and Interpretation of data, Writing-original draft preparation)

VN (Writing-review and editing)

MC (Writing-review and editing)

AAM (Writing-review and editing, Visualization)

AC (Conceptualization, Methodology, Resources, DNA isolation, Genotyping, Validation)

Conflict of interest statement

The authors declare that there are no conflicts of interest.

References

1. Sarafoleanu D. Tumorile maligne ale laringelui. In: Sarafoleanu C, editor. Esențialul în laringologie. Editura Academiei Române. București. 2007. p. 322-351.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature*. 2008 Jul 24;454(7203):436-44. DOI: 10.1038/nature07205
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011 Mar 4;144(5):646-74. DOI: 10.1016/j.cell.2011.02.013
4. Peltanova B, Raudenska M, Masarik M. Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. *Molecular Cancer*. 2019 Mar 30;18(1):63. DOI: 10.1186/s12943-019-0983-5
5. Barnes L, Tse LLY, Hunt JL, Brandwein-Gensler M, Urken M, Sliotwef P, et al. Tumours of the hypophar-

- ynx, larynx and trachea: Introduction. In: Barnes L, Evenson JW, Reichart P, Sidransky D, editors. World Health Classification of Tumors Pathology and Genetics of Head and Neck Tumors. IARC Press. Lyon. 2005. p.109-120.
6. Armstrong WB, Vokes DE, Verma SP. Malignant tumors of the larynx. In: Flint PW, Haughey BH, Lund V, Niparko JK, Robbins KT, Thomas JR, Lesperance MM, editors. Cummings Otolaryngology Head and Neck surgery. Sixth Edition. Elsevier. Philadelphia. 2014. p.1880-1923.
7. Akira S, Uematsu S, Takeuchi O. Pathogen Recognition and Innate Immunity. Cell. 2006 Feb 24;124(4):783-801. DOI: 10.1016/j.cell.2006.02.015
8. Ferwerda B, McCall MB, Verheijen K, Kullberg B-J, van der Ven AJ, Van der Meer JW, et al. Functional Consequences of Toll-like Receptor 4 Polymorphisms. Mol Med. 2008;14(5-6):346-52. DOI: 10.2119/2007-00135.Ferwerda
9. Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol. 2011;2011:609579. DOI: 10.1155/2011/609579
10. Sato Y, Goto Y, Narita N, Hoon DSB. Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron. 2009 Aug 15;2(Suppl 1):205-14. DOI: 10.1007/s12307-009-0022-y
11. Mai CW, Kang YB, Pichika MR. Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther. 2013 Nov 5;6:1573-87. DOI: 10.2147/OTT.S50838
12. Zhu L, Yuan H, Jiang T, Wang R, Ma H, Zhang S. Association of TLR2 and TLR4 Polymorphisms with Risk of Cancer: A Meta-Analysis. PLOS ONE. 2013 Dec 20;8(12):e82858. DOI: 10.1371/journal.pone.0082858
13. Sancar A. Mechanisms of DNA excision repair. Science. 1994 Dec 23;266(5193):1954-6. DOI: 10.1126/science.7801120
14. Torgovnick A, Schumacher B. DNA repair mechanisms in cancer development and therapy. Front Genet. 2015; 6: 157 DOI: 10.3389/fgene.2015.00157
15. Berwick M, Vineis P. Markers of DNA Repair and Susceptibility to Cancer in Humans: an Epidemiologic Review. J Natl Cancer Inst. 2000 Jun 7;92(11):874-97. DOI: 10.1093/jnci/92.11.874
16. Caldecott KW, Aoufouchi S, Johnson P, Shall S. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular "nick-sensor" in vitro. Nucleic Acids Res. 1996 Nov 15;24(22):4387-94. DOI: 10.1093/nar/24.22.4387
17. Khelifi R, Rebai A, Hamza-Chaffai A. Polymorphisms in human DNA repair genes and head and neck squamous cell carcinoma. J Genet. 2012 Dec 1;91(3):375-84. DOI: 10.1007/s12041-012-0193-z
18. Wang M, Chu H, Zhang Z, Wei Q. Molecular epidemiology of DNA repair gene polymorphisms and head and neck cancer. J Biomed Res. 2013 May;27(3):179-92.
19. Feng YZ, Liu YL, He XF, Wei W, Shen XL, Xie DL. Association between the XRCC1 Arg194Trp polymorphism and risk of cancer: evidence from 201 case-control studies. Tumor Biol. 2014 Nov 1;35(11):10677-97. DOI: 10.1007/s13277-014-2326-x
20. Yi L, Xiao-feng H, Yun-tao L, Hao L, Ye S, Song-tao Q. Association between the XRCC1 Arg399Gln Polymorphism and Risk of Cancer: Evidence from 297 Case-Control Studies. PLOS ONE. 2013;8(10):e78071. DOI: 10.1371/journal.pone.0078071
21. Schultz P, Fribourg S, Poterszman A, Mallouh V, Moras D, Egly JM. Molecular Structure of Human TFI-IH. Cell. 2000 Sep 1;102(5):599-607. DOI: 10.1016/S0092-8674(00)00082-9
22. Chen J, Suter B. Xpd, a Structural Bridge and a Functional Link. Cell Cycle. 2003 Nov 28;2(6):503-6. DOI: 10.4161/cc.2.6.558
23. Fan L, Fuss JO, Cheng QJ, Arvai AS, Hammel M, Roberts VA, et al. XPD Helicase Structures and Activities: Insights into the Cancer and Aging Phenotypes from XPD Mutations. Cell. 2008 May 30;133(5):789-800. DOI: 10.1016/j.cell.2008.04.030
24. Coin F, Marinoni J-C, Rodolfo C, Fribourg S, Pedrini AM, Egly J-M. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIH. Nat Genet. 1998 Oct;20(2):184-8. DOI: 10.1038/2491
25. Mitra AK, Singh N, Garg VK, Chaturvedi R, Sharma M, Rath SK. Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer in the north Indian population. J Exp Clin Cancer Res. 2009 Jul 18;28(1):104. DOI: 10.1186/1756-9966-28-104
26. Fu W, Xiao F, Zhang R, Li J, Zhao D, Lin X, et al. Association Between the Asp312Asn, Lys751Gln,

- and Arg156Arg Polymorphisms in XPD and the Risk of Prostate Cancer. *Technol Cancer Res Treat*. 2017 Dec;16(6):692-704. DOI: 10.1177/1533034617724678
27. Yin J, Vogel U, Ma Y, Guo L, Wang H, Qi R. Polymorphism of the DNA repair gene ERCC2 Lys751Gln and risk of lung cancer in a northeastern Chinese population. *Cancer Genetics and Cytogenetics*. 2006 Aug 1;169(1):27-32. DOI: 10.1016/j.cancergencyto.2006.03.008
 28. Procopciuc LM, Osian G. Interaction between lifestyle factors and the XRCC1, XPD, and XRCC3 genetic variations modulates the risk for sporadic colorectal cancer. *Revista Romana de Medicina de Laborator*. 2014 Mar 1;22(1):129-41. DOI: 10.2478/rrlm-2014-0002
 29. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. *JAMA*. 2013 Nov 27;310(20):2191-4. DOI: 10.1001/jama.2013.281053
 30. de Miguel-Luken MJ, Chaves-Conde M, Carnero A. A genetic view of laryngeal cancer heterogeneity. *Cell Cycle*. 2016 Mar 3;15(9):1202-12. DOI: 10.1080/15384101.2016.1156275
 31. Szczepański M, Stelmachowska M, Stryczyński L, Golusiński W, Samara H, Mozer-Lisewska I, et al. Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. *Eur Arch Otorhinolaryngol*. 2007 May;264(5):525-30. DOI: 10.1007/s00405-006-0215-7
 32. Sikora J, Frydrychowicz M, Kaczmarek M, Brzezicha B, Mozer-Lisewska I, Szczepański M, et al. TLR receptors in laryngeal carcinoma - immunophenotypic, molecular and functional studies. *Folia Histochemica et Cytobiologica*. 2010 Dec 1;48(4):624-31. DOI: 10.2478/v10042-010-0077-0
 33. Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Pütter C, Wild CA, et al. Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. *J Transl Med*. 2011 Aug 21;9:139. DOI: 10.1186/1479-5876-9-139
 34. Ding L, Jiang Q, Li G, Shen J, Du J, Lu X, et al. Comprehensive assessment of association between TLR4 gene polymorphisms and cancer risk: a systematic meta-analysis. *Oncotarget*. 2017 Nov 21;8(59):100593-602. DOI: 10.18632/oncotarget.21543
 35. Alimu N, Qukuerhan A, Wang S, Abdurehim Y, Kuyaxi P, Zhang B, et al. The association between XRCC1 polymorphism and laryngeal cancer susceptibility in different ethnic groups in Xinjiang, China. *Int J Clin Exp Pathol*. 2018 Sep 1;11(9):4595-604.
 36. Li F, Wang J, Chen M. Single nucleotide polymorphisms in DNA repair genes and the risk of laryngeal cancer: A meta-analysis. *Biomedicine & Pharmacotherapy*. 2016 Mar 1;78:92-100. DOI: 10.1016/j.biopha.2015.12.019
 37. Olshan AF, Watson MA, Weissler MC, Bell DA. XRCC1 polymorphisms and head and neck cancer. *Cancer Lett*. 2002;178:181-6 DOI: 10.1016/S0304-3835(01)00822-9
 38. Huang W-Y, Olshan AF, Schwartz SM, Berndt SI, Chen C, Llaça V, et al. Selected Genetic Polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and Risk of Head and Neck Cancer: A Pooled Analysis. *Cancer Epidemiol Biomarkers Prev*. 2005 Jul 1;14(7):1747-53. DOI: 10.1158/1055-9965.EPI-05-0162
 39. Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. *Cancer Epidemiol Biomarkers Prev*. 2005 Jul;14(7):1810-1818 DOI: 10.1158/1055-9965.EPI-04-0793
 40. Varzim G, Monteiro E, Silva RA, Fernandes J, Lopes C. CYP1A1 and XRCC1 gene polymorphisms in SCC of the larynx. *Eur J of Cancer Prev*. 2003 Dec;12(6):495-9. DOI: 10.1097/00008469-200312000-00008
 41. Chen W, Wang ZY, Xu FL, Wu KM, Zhang Y, Xu L, et al. Association of XRCC1 genetic polymorphism (Arg399Gln) with laryngeal cancer: a meta-analysis based on 4,031 subjects. *Tumor Biol*. 2014 Feb 1;35(2):1637-40. DOI: 10.1007/s13277-013-1225-x
 42. Wu WQ, Zhang LS, Liao SP, Lin XL, Zeng J, Du D. Association between XRCC1 polymorphisms and laryngeal cancer susceptibility in a Chinese sample population. *Genet Mol Res*. 2016 Oct 5;15(4). DOI: 10.4238/gmr.15048525
 43. Yuan H, Li H, Ma H, Niu Y, Wu Y, Zhang S, et al. Genetic polymorphisms in key DNA repair genes and risk of head and neck cancer in a Chinese population. *Exp Ther Med*. 2012 Apr;3(4):719-24. DOI: 10.3892/etm.2012.476
 44. Wu W, Liu L, Yin Z, Guan P, Li X, Zhou B. Association of X-Ray Repair Cross-Complementing Group 1 Arg194Trp, Arg399Gln and Arg280His Polymorphisms with Head and Neck Cancer Susceptibility: A Meta-Analysis. *PLOS ONE*. 2014;9(1):e86798. DOI: 10.1371/journal.pone.0086798

45. Lou Y, Peng W, Cao D, Xie J, Li H, Jiang Z. DNA Repair Gene XRCC1 Polymorphisms and Head and Neck Cancer Risk: An Updated Meta-Analysis Including 16344 Subjects. PLOS ONE. 2013 Sep 23;8(9):e74059. DOI: 10.1371/journal.pone.0074059
46. Lin H, Lin D, Zheng C. Association of XPD Lys751Gln polymorphism with head and neck cancer susceptibility: evidence from 11,443 subjects. Diagn Pathol. 2014 Jan 20;9:15. DOI: 10.1186/1746-1596-9-15
47. Yuan H, Niu YM, Wang RX, Li HZ, Chen N. Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis. Genet Mol Res. 2011;10(4):3356-64 DOI: 10.4238/2011.November.22.6
48. Hou S-M, Ryk C, Kannio A, Angelini S, Fält S, Nyberg F, et al. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors. Environmental and molecular mutagenesis. 2003 Feb 1;41:37-42. DOI: 10.1002/em.10128
49. Zhong S, Nukui T, Buch S, Diergaarde B, Weissfeld LA, Grandis J, et al. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent. Cancer Epidemiol Biomarkers Prev. 2011 Nov;20(11):2429-37. DOI: 10.1158/1055-9965.EPI-11-0520
50. An J, Liu Z, Hu Z, Li G, Wang L-E, Sturgis EM, et al. Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev. 2007 Aug 1;16(8):1633-8 DOI: 10.1158/1055-9965.EPI-07-0252
51. Sun Y, Tan L, Li H, Qin X, Liu J. Association of NER pathway gene polymorphisms with susceptibility to laryngeal cancer in a Chinese population. Int J Clin Exp Pathol. 2015 Sep 1;8(9):11615-21.